Head to Head Comparison: Beta Bionics (NASDAQ:BBNX) & Olympus (OTCMKTS:OCPNY)

Olympus (OTCMKTS:OCPNY) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Risk & Volatility

Olympus has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Olympus shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Olympus and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Olympus	13.80%	24.30%	9.30%
Beta Bionics	-65.31%	-27.33%	-24.28%

Analyst Recommendations

This is a summary of current recommendations and price targets for Olympus and Beta Bionics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olympus	0	0	1	0	3.00
Beta Bionics	1	4	9	1	2.67

Beta Bionics has a consensus target price of $23.69, suggesting a potential upside of 42.05%. Given Beta Bionics’ higher possible upside, analysts plainly believe Beta Bionics is more favorable than Olympus.

Valuation and Earnings

This table compares Olympus and Beta Bionics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olympus	$7.74 billion	2.99	$1.03 billion	$0.82	21.95
Beta Bionics	$100.25 million	9.05	-$73.20 million	($1.84)	-9.06

Olympus has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Summary

Olympus beats Beta Bionics on 9 of the 15 factors compared between the two stocks.

About Olympus

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.